Abstract: . . .  of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17 : 100107. 18 Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315 : 157782. 19 Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999; 42 : 1293301. 20 British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: . . .
. . .  et al. Cholesterol- lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease : is it cost-effective? Med J Aust 2002; 177 : 42834. 17 Jonsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17 : 100107. 18 Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315 : 157782. 19 Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: . . .
. . .  Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361 : 200516. 4Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high risk conditions. Lancet 2004; 363 : 75767. 5 NHS Executive. Trust financial returns. Leeds: NHS Executive, 2001. 6 NHS Executive. Trust financial returns. Leeds: NHS Executive, 2002. 7 Joint Formulary Committee. British National Formulary 41. London: British Medical Association . . .
. . .  of apparently similar people in different circumstances. Consequently, the exact definition of the multivariate risk groups used in the present analyses is not particularly relevant to the extrapolation of the findings. However, these estimates of cost-effectiveness at different levels of risk are likely to be generalisable to a wide range of different settings using appropriate local data to estimate the risks for particular individuals. Current guidelines 20,21 generally recommend the initiation of statin therapy when the estimated 10-year risk of a non-fatal heart attack or coronary death is at least 1520%. Previous analyses of HPS 24 have demonstrated . . .
--3000,4,375,3315,45072